Welcome to Career Coach, a column for job seekers and employees navigating the ins and outs of finding, landing and succeeding in jobs in the biotech industry. Each month, Carina Clingman, founder of ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Year-over-year BioSpace data shows there were fewer job postings live on the website in the fourth quarter of 2024, and the ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...